Status:
TERMINATED
Study Investigating the Long-Term Safety and Tolerability of Repeated Doses of Degarelix in Prostate Cancer Patients
Lead Sponsor:
Ferring Pharmaceuticals
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
PHASE2
Brief Summary
To investigate the long-term safety and tolerability of repeated doses of degarelix to prostate cancer patients
Detailed Description
Degarelix was not FDA regulated at the time of the trial. After completion of the trial degarelix has been approved by the FDA and is thus an FDA regulated intervention (FDA regulated intervention is ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Has completed study treatment in study FE200486 CS02.
- Has completed visit 16 in study FE200486 CS02.
- Has not met any withdrawal criteria up to and including visit 15 in FE200486 CS02
Exclusion
Key Trial Info
Start Date :
October 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2006
Estimated Enrollment :
88 Patients enrolled
Trial Details
Trial ID
NCT00245466
Start Date
October 1 2001
End Date
March 1 2006
Last Update
May 20 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.